PSTV 8-K — Smart Summary
77% reductionPlus Therapeutics, Inc. (PSTV) disclosed that a Nasdaq Hearings Panel granted the company continued listing on Nasdaq, subject to the company demonstrating compliance with minimum stockholders' equity and minimum bid price requirements by specified deadlines.
Item 8.01 — Other Events
Other
- On June 3, 2025, Nasdaq notified the company of non-compliance with Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity
- Company reported stockholders' equity (deficit) of ($23,641,000) as of March 31, 2025, failing the Minimum Stockholders' Equity Requirement
- Company requested a hearing; hearing took place on July 15, 2025
- On July 22, 2025, the Hearings Panel granted continued listing subject to two conditions: (1) demonstrating compliance with the Minimum Stockholders' Equity Requirement by August 14, 2025 via public disclosure of transactions undertaken to achieve and sustain compliance; and (2) achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days on or before September 8, 2025
§ MORE SUMMARIES
More PSTV Smart Summaries
Other filings for PLUS THERAPEUTICS, INC. with a Smart Summary.
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Never miss a PSTV filing
Get real-time email alerts when PSTV files with the SEC.